Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial empiric linezolid combination therapy in febrile neutropenia
ChiCTR-IPR-16008828Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of linezolid and imipenem + cilastatin in febrile neutropenia (FN) (2 arms), sponsored by Shanghai General Hospital. Primary endpoints: Defervescence time, Clinical effective rate and 1 more. Planned start Aug 2016; status: not yet recruiting.
02
Drugs
linezolidimipenem + cilastatin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR-IPR-16008828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008828.